Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
PODD.US
id: 1222

Insulet Corporation (PODD) End of Product Monopoly Case

  • On May 14, 2024, Blue Orca Capital announced a short position on Insulet Corporation.
  • In two consecutive trading sessions on May 10 and May 13, 2024, $PODD lost $1.15B+ of shareholder value.
  • Investors may have grounds to suspect Insulet of hiding material negative information about its business, which led to their losses.
Blue Orca claims that the Court of Appeals for the Federal Curcuit recently overturned a preliminary injunction that protected Insulet's monopoly on tubeless insulin delivery systems, effectively opening the market for competition.

Blue Orca expects immediate negative impact for $PODD in new competitive market.

Considering all the information, investors might have grounds to suspect Insulet of failing to disclose important facts, which led to their losses.
Case Status
Attorney Investigation
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
10 May 2024
Collecting participants…

Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin De...

    Ticker
    PODD.US
    ISIN
    US45784P1012
    CIK
    1145197
    Sector
    Healthcare
    Industry
    Medical Devices
    Country
    USA
    Address
    100 Nagog Park, Acton, MA, United States, 01720